Matrilysin/matrix metalloproteinase-7(MMP7) cleavage of perlecan/HSPG2 creates a molecular switch to alter prostate cancer cell behavior

Matrix Biology

Volumn 36, Issue , 2014, Pages 64-76

  Grindel, B J ^a   Martinez, J R ^a   Pennington, C L ^a   Muldoon, M ^c   Stave, J ^c   Chung, L W ^d   Farach Carson, M C ^a,b  

^a RICE UNIVERSITY   (United States)

^b Rice University   (United States)

^c Strategic Diagnostics Incorporated   (United States)

^d CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Matrilysin; Matrix metalloproteinase 7 MMP7; Perlecan HSPG2; Prostate cancer

Indexed keywords

HEPSIN; IMMUNOGLOBULIN; MATRILYSIN; PERLECAN; PROSTATE SPECIFIC ANTIGEN; MMP7 PROTEIN, HUMAN; PROTEOHEPARAN SULFATE; SCLEROPROTEIN;

ARTICLE; CANCER CELL; CELL ACTIVATION; CELL FUNCTION; CELL INVASION; CONTROLLED STUDY; DISPERSION; FIBROBLAST; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; PROSTATE CANCER; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN PURIFICATION; TUMOR MICROENVIRONMENT; BASEMENT MEMBRANE; ENDOTHELIUM CELL; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; PROSTATE TUMOR; TRANSCRIPTION INITIATION; TUMOR INVASION;

BASEMENT MEMBRANE; ENDOTHELIAL CELLS; EXTRACELLULAR MATRIX PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPARAN SULFATE PROTEOGLYCANS; HUMANS; MALE; MATRIX METALLOPROTEINASE 7; NEOPLASM INVASIVENESS; PROSTATIC NEOPLASMS; PROTEOLYSIS; TRANSCRIPTIONAL ACTIVATION; TUMOR MICROENVIRONMENT;

EID: 84909966044     PISSN: 0945053X     EISSN: 15691802     Source Type: Journal    
DOI: 10.1016/j.matbio.2014.04.005     Document Type: Article

References (68)

1. Amalinei C., Caruntu I.D., Balan R.A. Biology of metalloproteinases. Rom. J. Morphol. Embryol. 2007, 48:323-334.
2. Balasubramani M., Bier M.E., Hummel S., Schneider W.J., Halfter W. Perlecan and its immunoglobulin like domain IV are abundant in vitreous and serum of the chick embryo. Matrix Biol. 2004, 23:143-152.
3. Behrens D.T., Villone D., Koch M., Brunner G., Sorokin L., Robenek H., Bruckner-Tuderman L., Bruckner P., Hansen U. The epidermal basement membrane is a composite of separate laminin- or collagen IV-containing networks connected by aggregated perlecan, but not by nidogens. J. Biol. Chem. 2012, 287:18700-18709.
4. Bix G., Fu J., Gonzalez E.M., Macro L., Barker A., Campbell S., Zutter M.M., Santoro S.A., Kim J.K., Hook M., Reed C.C., Iozzo R.V. Endorepellin causes endothelial cell disassembly of actin cytoskeleton and focal adhesions through alpha2beta1 integrin. J. Cell Biol. 2004, 166:97-109.
5. Brown A.J., Alicknavitch M., D'Souza S.S., Daikoku T., Kirn-Safran C.B., Marchetti D., Carson D.D., Farach-Carson M.C. Heparanase expression and activity influences chondrogenic and osteogenic processes during endochondral bone formation. Bone 2008, 43:689-699.
6. Cailhier J.F., Sirois I., Laplante P., Lepage S., Raymond M.A., Brassard N., Prat A., Iozzo R.V., Pshezhetsky A.V., Hebert M.J. Caspase-3 activation triggers extracellular cathepsin L release and endorepellin proteolysis. J. Biol. Chem. 2008, 283:27220-27229.
7. Cardillo M.R., Di Silverio F., Gentile V. Quantitative immunohistochemical and in situ hybridization analysis of metalloproteinases in prostate cancer. Anticancer Res. 2006, 26:973-982.
8. Chang J.H., Javier J.A., Chang G.Y., Oliveira H.B., Azar D.T. Functional characterization of neostatins, the MMP-derived, enzymatic cleavage products of type XVIII collagen. FEBS Lett. 2005, 579:3601-3606.
9. Christiansen V.J., Jackson K.W., Lee K.N., McKee P.A. Effect of fibroblast activation protein and alpha2-antiplasmin cleaving enzyme on collagen types I, III, and IV. Arch. Biochem. Biophys. 2007, 457:177-186.
10. Datta M.W., Hernandez A.M., Schlicht M.J., Kahler A.J., DeGueme A.M., Dhir R., Shah R.B., Farach-Carson C., Barrett A., Datta S. Perlecan, a candidate gene for the CAPB locus, regulates prostate cancer cell growth via the Sonic Hedgehog pathway. Mol. Cancer 2006, 5:9.
11. d'Ortho M.P., Will H., Atkinson S., Butler G., Messent A., Gavrilovic J., Smith B., Timpl R., Zardi L., Murphy G. Membrane-type matrix metalloproteinases 1 and 2 exhibit broad-spectrum proteolytic capacities comparable to many matrix metalloproteinases. Eur. J. Biochem. 1997, 250:751-757.
12. Farach-Carson M.C., Brown A.J., Lynam M., Safran J.B., Carson D.D. A novel peptide sequence in perlecan domain IV supports cell adhesion, spreading and FAK activation. Matrix Biol. 2008, 27:150-160.
13. Farach-Carson M.C., Warren C.R., Harrington D.A., Carson D.D. Border patrol: Insights into the unique role of perlecan/heparan sulfate proteoglycan 2 at cell and tissue borders. Matrix Biol. 2014, 34:64-79. (Epub ahead of print).
14. Fosang A.J., Neame P.J., Last K., Hardingham T.E., Murphy G., Hamilton J.A. The interglobular domain of cartilage aggrecan is cleaved by PUMP, gelatinases, and cathepsin B. J. Biol. Chem. 1992, 267:19470-19474.
15. Fu X., Kassim S.Y., Parks W.C., Heinecke J.W. Hypochlorous acid oxygenates the cysteine switch domain of pro-matrilysin (MMP-7). A mechanism for matrix metalloproteinase activation and atherosclerotic plaque rupture by myeloperoxidase. J. Biol. Chem. 2001, 276:41279-41287.
16. Fuki I.V., Iozzo R.V., Williams K.J. Perlecan heparan sulfate proteoglycan: a novel receptor that mediates a distinct pathway for ligand catabolism. J. Biol. Chem. 2000, 275:25742-25750.
17. Giannelli G., Falk-Marzillier J., Schiraldi O., Stetler-Stevenson W.G., Quaranta V. Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5. Science 1997, 277:225-228.
18. Gohring W., Sasaki T., Heldin C.H., Timpl R. Mapping of the binding of platelet-derived growth factor to distinct domains of the basement membrane proteins BM-40 and perlecan and distinction from the BM-40 collagen-binding epitope. Eur. J. Biochem. 1998, 255:60-66.
19. Gonzalez E.M., Reed C.C., Bix G., Fu J., Zhang Y., Gopalakrishnan B., Greenspan D.S., Iozzo R.V. BMP-1/Tolloid-like metalloproteases process endorepellin, the angiostatic C-terminal fragment of perlecan. J. Biol. Chem. 2005, 280:7080-7087.
20. Gurski L.A., Jha A.K., Zhang C., Jia X., Farach-Carson M.C. Hyaluronic acid-based hydrogels as 3D matrices for in vitro evaluation of chemotherapeutic drugs using poorly adherent prostate cancer cells. Biomaterials 2009, 30:6076-6085.
21. Hart C.A., Scott L.J., Bagley S., Bryden A.A., Clarke N.W., Lang S.H. Role of proteolytic enzymes in human prostate bone metastasis formation: in vivo and in vitro studies. Br. J. Cancer 2002, 86:1136-1142.
22. Hashimoto K., Kihira Y., Matuo Y., Usui T. Expression of matrix metalloproteinase-7 and tissue inhibitor of metalloproteinase-1 in human prostate. J. Urol. 1998, 160:1872-1876.
23. Heinz A., Jung M.C., Duca L., Sippl W., Taddese S., Ihling C., Rusciani A., Jahreis G., Weiss A.S., Neubert R.H., Schmelzer C.E. Degradation of tropoelastin by matrix metalloproteinases-cleavage site specificities and release of matrikines. FEBS J. 2010, 277:1939-1956.
24. Heremans A., van der Schueren B., de Cock B., Paulsson M., Cassiman J.J., van den Berghe H., David G. Matrix-associated heparan sulfate proteoglycan: core protein-specific monoclonal antibodies decorate the pericellular matrix of connective tissue cells and the stromal side of basement membranes. J. Cell Biol. 1989, 109:3199-3211.
25. Hopf M., Gohring W., Kohfeldt E., Yamada Y., Timpl R. Recombinant domain IV of perlecan binds to nidogens, laminin-nidogen complex, fibronectin, fibulin-2 and heparin. Eur. J. Biochem. 1999, 259:917-925.
26. Imai K., Shikata H., Okada Y. Degradation of vitronectin by matrix metalloproteinases-1, -2, -3, -7 and -9. FEBS Lett. 1995, 369:249-251.
27. Iozzo R.V. Biosynthesis of heparan sulfate proteoglycan by human colon carcinoma cells and its localization at the cell surface. J. Cell Biol. 1984, 99:403-417.
28. Iozzo R.V., Zoeller J.J., Nystrom A. Basement membrane proteoglycans: modulators Par Excellence of cancer growth and angiogenesis. Mol. Cells 2009, 27:503-513.
29. Ishijima M., Suzuki N., Hozumi K., Matsunobu T., Kosaki K., Kaneko H., Hassell J.R., Arikawa-Hirasawa E., Yamada Y. Perlecan modulates VEGF signaling and is essential for vascularization in endochondral bone formation. Matrix Biol. 2012, 31:234-245.
30. Jarkovska K., Martinkova J., Liskova L., Halada P., Moos J., Rezabek K., Gadher S.J., Kovarova H. Proteome mining of human follicular fluid reveals a crucial role of complement cascade and key biological pathways in women undergoing in vitro fertilization. J. Proteome Res. 2010, 9:1289-1301.
31. Josson S., Matsuoka Y., Chung L.W., Zhau H.E., Wang R. Tumor-stroma co-evolution in prostate cancer progression and metastasis. Semin. Cell Dev. Biol. 2010, 21:26-32.
32. Kaneko H., Ishijima M., Futami I., Tomikawa-Ichikawa N., Kosaki K., Sadatsuki R., Yamada Y., Kurosawa H., Kaneko K., Arikawa-Hirasawa E. Synovial perlecan is required for osteophyte formation in knee osteoarthritis. Matrix Biol. 2013, 32:178-187.
33. Kelley L.A., Sternberg M.J. Protein structure prediction on the Web: a case study using the Phyre server. Nat. Protoc. 2009, 4:363-371.
34. Kelly T., Huang Y., Simms A.E., Mazur A. Fibroblast activation protein-alpha: a key modulator of the microenvironment in multiple pathologies. Int. Rev. Cell Mol. Biol. 2012, 297:83-116.
35. Kennett E.C., Chuang C.Y., Degendorfer G., Whitelock J.M., Davies M.J. Mechanisms and consequences of oxidative damage to extracellular matrix. Biochem. Soc. Trans. 2011, 39:1279-1287.
36. Klein G., Conzelmann S., Beck S., Timpl R., Muller C.A. Perlecan in human bone marrow: a growth-factor-presenting, but anti-adhesive, extracellular matrix component for hematopoietic cells. Matrix Biol. 1995, 14:457-465.
37. Lamanna W.C., Frese M.A., Balleininger M., Dierks T. Sulf loss influences N-, 2-O-, and 6-O-sulfation of multiple heparan sulfate proteoglycans and modulates fibroblast growth factor signaling. J. Biol. Chem. 2008, 283:27724-27735.
38. Lee B., Clarke D., Al Ahmad A., Kahle M., Parham C., Auckland L., Shaw C., Fidanboylu M., Orr A.W., Ogunshola O., Fertala A., Thomas S.A., Bix G.J. Perlecan domain V is neuroprotective and proangiogenic following ischemic stroke in rodents. J. Clin. Invest. 2011, 121:3005-3023.
39. Lynch C.C., Hikosaka A., Acuff H.B., Martin M.D., Kawai N., Singh R.K., Vargo-Gogola T.C., Begtrup J.L., Peterson T.E., Fingleton B., Shirai T., Matrisian L.M., Futakuchi M. MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL. Cancer Cell 2005, 7:485-496.
40. Mongiat M., Sweeney S.M., San Antonio J.D., Fu J., Iozzo R.V. Endorepellin, a novel inhibitor of angiogenesis derived from the C terminus of perlecan. J. Biol. Chem. 2003, 278:4238-4249.
41. Oda O., Shinzato T., Ohbayashi K., Takai I., Kunimatsu M., Maeda K., Yamanaka N. Purification and characterization of perlecan fragment in urine of end-stage renal failure patients. Clin. Chim. Acta 1996, 255:119-132.
42. Pajouh M.S., Nagle R.B., Breathnach R., Finch J.S., Brawer M.K., Bowden G.T. Expression of metalloproteinase genes in human prostate cancer. J. Cancer Res. Clin. Oncol. 1991, 117:144-150.
43. Perkins D.N., Pappin D.J., Creasy D.M., Cottrell J.S. Probability-based protein identification by searching sequence databases using mass spectrometry data. Electrophoresis 1999, 20:3551-3567.
44. Platz E.A., De Marzo A.M. Epidemiology of inflammation and prostate cancer. J. Urol. 2004, 171:S36-S40.
45. Polyak K., Weinberg R.A. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat. Rev. Cancer 2009, 9:265-273.
46. Powell W.C., Knox J.D., Navre M., Grogan T.M., Kittelson J., Nagle R.B., Bowden G.T. Expression of the metalloproteinase matrilysin in DU-145 cells increases their invasive potential in severe combined immunodeficient mice. Cancer Res. 1993, 53:417-422.
47. Ra H.J., Harju-Baker S., Zhang F., Linhardt R.J., Wilson C.L., Parks W.C. Control of promatrilysin (MMP7) activation and substrate-specific activity by sulfated glycosaminoglycans. J. Biol. Chem. 2009, 284:27924-27932.
48. Reiland J., Sanderson R.D., Waguespack M., Barker S.A., Long R., Carson D.D., Marchetti D. Heparanase degrades syndecan-1 and perlecan heparan sulfate: functional implications for tumor cell invasion. J. Biol. Chem. 2004, 279:8047-8055.
49. Ritchey E.R., Code K., Zelinka C.P., Scott M.A., Fischer A.J. The chicken cornea as a model of wound healing and neuronal re-innervation. Mol. Vis. 2011, 17:2440-2454.
50. Rowe R.G., Weiss S.J. Breaching the basement membrane: who, when and how?. Trends Cell Biol. 2008, 18:560-574.
51. Strohalm M., Hassman M., Kosata B., Kodicek M. mMass data miner: an open source alternative for mass spectrometric data analysis. Rapid Commun. Mass Spectrom. 2008, 22:905-908.
52. Strohalm M., Kavan D., Novak P., Volny M., Havlicek V. mMass 3: a cross-platform software environment for precise analysis of mass spectrometric data. Anal. Chem. 2010, 82:4648-4651.
53. Thalmann G.N., Sikes R.A., Wu T.T., Degeorges A., Chang S.M., Ozen M., Pathak S., Chung L.W. LNCaP progression model of human prostate cancer: androgen-independence and osseous metastasis. Prostate 2000, 44:91-103. (Jul 101;144(102)).
54. Tilakaratne W.M., Kobayashi T., Ida-Yonemochi H., Swelam W., Yamazaki M., Mikami T., Alvarado C.G., Shahidul A.M., Maruyama S., Cheng J., Saku T. Matrix metalloproteinase 7 and perlecan in oral epithelial dysplasia and carcinoma in situ: an aid for histopathologic recognition of their cell proliferation centers. J. Oral Pathol. Med. 2009, 38:348-355.
55. Tripathi M., Nandana S., Yamashita H., Ganesan R., Kirchhofer D., Quaranta V. Laminin-332 is a substrate for hepsin, a protease associated with prostate cancer progression. J. Biol. Chem. 2008, 283:30576-30584.
56. Turk B.E., Huang L.L., Piro E.T., Cantley L.C. Determination of protease cleavage site motifs using mixture-based oriented peptide libraries. Nat. Biotechnol. 2001, 19:661-667.
57. Tuxhorn J.A., Ayala G.E., Smith M.J., Smith V.C., Dang T.D., Rowley D.R. Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling. Clin. Cancer Res. 2002, 8:2912-2923.
58. Verspurten J., Gevaert K., Declercq W., Vandenabeele P. SitePredicting the cleavage of proteinase substrates. Trends Biochem. Sci. 2009, 34:319-323.
59. Vuadens F., Benay C., Crettaz D., Gallot D., Sapin V., Schneider P., Bienvenut W.V., Lemery D., Quadroni M., Dastugue B., Tissot J.D. Identification of biologic markers of the premature rupture of fetal membranes: proteomic approach. Proteomics 2003, 3:1521-1525.
60. Warren C.R., Grindel B.J., Farach-Carson M.C., Carson D. Perlecan/HSPG2 increases in the desmoplastic prostate tumor microenvironment involve transcriptional activation by nuclear factor kappa B. Clin. Exp. Metastasis 2014, 115(7):1322-1333.
61. Webber M.M., Waghray A., Bello D. Prostate-specific antigen, a serine protease, facilitates human prostate cancer cell invasion. Clin. Cancer Res. 1995, 1:1089-1094.
62. Welch A.R., Holman C.M., Huber M., Brenner M.C., Browner M.F., Van Wart H.E. Understanding the P1' specificity of the matrix metalloproteinases: effect of S1' pocket mutations in matrilysin and stromelysin-1. Biochemistry 1996, 35:10103-10109.
63. Whitelock J.M., Murdoch A.D., Iozzo R.V., Underwood P.A. The degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase, plasmin, and heparanases. J. Biol. Chem. 1996, 271:10079-10086.
64. Whitelock J.M., Melrose J., Iozzo R.V. Diverse cell signaling events modulated by perlecan. Biochemistry 2008, 47:11174-11183.
65. Woessner J.F., Taplin C.J. Purification and properties of a small latent matrix metalloproteinase of the rat uterus. J. Biol. Chem. 1988, 263:16918-16925.
66. Wu H.C., Hsieh J.T., Gleave M.E., Brown N.M., Pathak S., Chung L.W. Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells. Int. J. Cancer 1994, 57:406-412.
67. Yu W.H., Woessner J.F. Heparan sulfate proteoglycans as extracellular docking molecules for matrilysin (matrix metalloproteinase 7). J. Biol. Chem. 2000, 275:4183-4191.
68. Zhang Z., Marshall A.G. A universal algorithm for fast and automated charge state deconvolution of electrospray mass-to-charge ratio spectra. J. Am. Soc. Mass Spectrom. 1998, 9:225-233.